VXRT · Vaxart, Inc. · Earnings Call Transcripts & Audio
$0.32
+0.00 (+0.00%)
At close · Jul 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on management's current plan, the Company expects to have enough cash runway into the second quarter of 2027. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, management's plans include further reducing or delaying operating expenses. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$126.27M
Shares
242.84M
Volume · Jul 8
11.57M
Avg daily vol (3M)
4.77M
Vaxart, Inc. Earnings Call Transcripts
Quarterly earnings calls for Vaxart, Inc. (VXRT), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼100%
$
−$29.31M
'22 Q3
22-11-08
▼70.3%
$22,000
−$23.92M
'22 Q4
23-03-16
▲694.1%
$675,000
−$25.14M
'23 Q1
23-05-09
·
$1.36M
−$22.55M
'23 Q2
23-08-03
·
$2.10M
−$17.40M
'23 Q3
23-11-02
▲14650%
$3.25M
−$17.38M
'23 Q4
24-03-14
▲223.1%
$2.18M
−$24.42M
'24 Q1
24-05-13
▲371.4%
$6.40M
−$16.47M
'24 Q2
24-08-08
▲134.8%
$4.93M
−$14.08M
'24 Q3
24-11-13
▲368%
$15.19M
−$11.98M
'24 Q4
25-03-21
▲857.2%
$20.88M
−$15.59M
'25 Q1
25-05-13
▲520.7%
$39.73M
−$14.99M
'25 Q2
25-08-13
▲1367.9%
$72.41M
−$8.14M
'25 Q3
25-11-13
▲586.5%
$104.24M
$55.05M
'25 Q4
26-03-12
▲87.9%
$39.23M
$5.18M
'26 Q1
26-05-08
LATEST
▼31.6%
$27.18M
−$13.49M
'26 Q2
26-08-06
Conference
Investor event
2026-09-14
Vaxart, Inc. (VXRT) September 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Vaxart, Inc. (VXRT) Q2 2026 Earnings Call
Revenue
$27.18M
▼ 31.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-08
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call
Revenue
$39.23M
▲ 87.9% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2026-03-13
Vaxart, Inc. (VXRT) March 2026 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-03-12
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Positive tone
Phase 2b COVID-19 sentinel cohort data
Dynavax/Sanofi COVID-19 partnership
Oral norovirus vaccine (lactating mothers data)
Revenue
$104.24M*
▲ 586.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Annual General Meeting
Investor event
2025-11-18
Vaxart, Inc. (VXRT) November 2025 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-13
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Confident tone
COVID market opportunity and strain adaptability
Dynavax partnership / business development
Norovirus program and partnership search
Revenue
$72.41M
▲ 1367.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Positive tone
Norovirus program
COVID-19 Phase IIb trial / BARDA stop work order
Partnering and business development
Revenue
$39.73M
▲ 520.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
Balanced tone
Norovirus vaccine program
COVID-19 Phase 2b trial restart
Reverse stock split and NASDAQ compliance
Revenue
$20.88M
▲ 857.2% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-21
Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript
Balanced tone
Norovirus Program
COVID-19 Program / Stop Work Order
Government and Regulatory Engagement
Revenue
$15.19M*
▲ 368% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Positive tone
Norovirus program
Regulatory engagement with FDA
Early-stage pipeline (HPV, flu, avian flu)
Revenue
$4.93M
▲ 134.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
Confident tone
BARDA / Project NextGen COVID funding
Norovirus program
Phase 2b COVID oral pill trial
Revenue
$6.40M
▲ 371.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
Positive tone
Norovirus vaccine in lactating mothers
COVID-19 Phase IIb trial and Project NextGen
New CEO leadership and execution
Revenue
$2.18M
▲ 223.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
Confident tone
COVID-19 oral vaccine program
Norovirus program
Leadership transition
Revenue
$3.25M*
▲ 14650% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript
Revenue
$2.10M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript
Revenue
$1.36M
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript
Revenue
$675,000
▲ 694.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript
Revenue
$22,000*
▼ 70.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Vaxart, Inc. (VXRT) Q2 2022 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls